Senator Jon Kyl and a group of Senators – including Sens. Mitch McConnell (Ky.), John Barrasso (R-Wyo.), Tom Coburn (R-Okla.), Mike Crapo (R-Idaho), and Pat Roberts (R-Kan.) have introduced critical legislation that seeks to protect the doctor and patient relationship from the oncoming onslaught of ObamaCare.

Known as the PATIENTS Act, the bill works to protect the individualized relationship between doctors and patients ensuring that new government rules and mandates that put a premium on cost never interfere with the practice of quality medicine.

To better understand how that will happen if ObamaCare is not defunded or repealed, it is critical to understand the nature of “comparative effectiveness research.” In order to save money for the cost of socialist health care regimes, bureaucrats often play the “comparative effectiveness research” card to mandate that doctors provide inferior care and treatment that often does not work.

These studies, for which there is nearly a billion dollars worth of funding in the ObamaCare bill, become the basis of bureaucratic mandates that substitute the government’s judgment for that of a doctor. For instance, if a government study says that drug X is as effective as drug Y (which is cheaper), the government will often begin to deny coverage for drug X forcing the doctor to use drug Y. In some instances, patients only respond to drug X. Doctors and patients should never be forced to take drugs that don’t work. Doctor’s need to be able to make these decisions without interference from a bureaucrat. That is what the Kyl bill seeks.

This is not a theoretical argument any longer.

(more…)

It’s hard not to imagine that some bureaucrats that the National Institute’s of Health were not thinking of Robert Burns’ “best laid plans of mice and men” when they heard the results of a recent “comparative effectiveness” study of the drugs Lucentis and Avastin.

“Comparative effectiveness” studies are the shoehorn for government interference between the doctor/patient relationship. These studies allow bureaucrats to dictate health care decisions that should be made by doctors by determining that certain drugs or treatments are comparable and the cheaper drug becomes the one the government covers for treatment. The ObamaCare takeover of our health care system appropriated nearly $1 billion for these studies.

The National Institute for Health (NIH) initiated a study into the “comparative effectiveness” of the drugs Lucentis and Avastin – both made by the same manufacture. The basis of the study was to determine whether Avastin could be used as a substitute for Lucentis when treated macular degeneration. Avastin was never approved by the FDA for macular degeneration while Lucentis was tried, tested and approved for such purpose.

The initial test results showed the danger of such a strategy.

(more…)